The effect of antifungal treatments on bronchoalveolar lavage galactomannan for the diagnosis of invasive fungal infections in patients with hematological malignancy: Single-center experience

Yıl 2024, Cilt: 6 Sayı: 2, 90 - 96, 29.04.2024

Müge Yaşar , Fahir Özkalemkaş , Beyza Ener , Ezgi Demirdöğen , Münevver İrem Kök , Vildan Ozkocaman

https://doi.org/10.46310/tjim.1361621

Öz

Background Invasive fungal infections (IFI) mainly caused by aspergillus species are one of the leading causes of death in patients undergoing immunosuppressive therapy for hematological malignancies. The presence of galactomannan in bronchoalveolar lavage fluid (BAL GM) is an important diagnostic marker. Some of the factors affecting the BAL GM are still unknown. Antifungal treatment administered before or after BAL also affect BAL GM results.
Methods To investigate the effect of BAL GM timing on the diagnosis of IFE, 100 patients receiving immunosuppressive therapy with hematological malignancy at the Uludağ University Faculty of Medicine, Hematology Department, and underwent BAL over a 3-year period with the suspicion of IFE as well as 127 BAL procedures of these patients were examined.
Results There were 70 patients who started antifungal therapy before BAL and 30 patients who did not. BAL GM was found positive in 33 (47.1%) of the 70 patients who received antifungal therapy compared to 22 (73.3%) of the 30 patients who did not receive antifungal therapy. There was a significant difference between the two groups in terms of BAL GM positivity (p = 0.016). Subsequently, 127 BAL procedures of these 100 patients were evaluated. When the second, third, and subsequent BAL procedures of the same patients were included in the study, BAL GM was positive in 41 (46.6%) of the 88 procedures in patients who received treatment before BAL and in 25 (64.1%) of the 39 procedures in patients who did not receive treatment before BAL. The rate of BAL GM positivity did not differ between groups (p = 0.068).
Conclusions The balance between reducing the risk by initiating early antifungal therapy and maximizing the diagnostic value of BAL GM should be evaluated individually for each patient.

Anahtar Kelimeler

Invasive fungal infection, bronchoalveolar lavage, galactomannan, hematological malignancy.

Destekleyen Kurum

It was presented at the 19th Uludağ Internal Medicine Congress

Kaynakça

• Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ; Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002 Jan 1;34(1):7-14. doi: 10.1086/323335.
• Maertens J, Maertens V, Theunissen K, Meersseman W, Meersseman P, Meers S, Verbeken E, Verhoef G, Van Eldere J, Lagrou K. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis. 2009 Dec 1;49(11):1688-93. doi: 10.1086/647935.
• De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, et.al.; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008 Jun 15;46(12):1813-21. doi: 10.1086/588660.
• de Kruif MD, Gerritsen MG, van Haren EH, Bel EH, Jonkers RE. Timing of broncho-alveolar lavage for galactomannan testing in hematological oncology patients. Clin Respir J. 2017 Jul;11(4):534-536. doi: 10.1111/crj.12380.
• Acet-Öztürk NA, Ömer-Topçu D, Vurat-Acar K, Aydın-Güçlü Ö, Pınar İE, Demirdöğen E, Görek-Dilektaşlı A, Kazak E, Özkocaman V, Ursavas A, Akalın H, Özkalemkaş F, Ener B, Ali R. Impact of revised EORTC/MSGERC 2020 criteria on diagnosis and prognosis of invasive pulmonary aspergillosis in patients with hematological malignancies undergoing bronchoscopy. J Mycol Med. 2022 Nov;32(4):101304. doi: 10.1016/j.mycmed.2022.101304.
• Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, Clancy CJ, Wingard JR, Lockhart SR, Groll AH, Sorrell TC, Bassetti M, Akan H, Alexander BD, Andes D, Azoulay E, Bialek R, Bradsher RW, Bretagne S, Calandra T, Caliendo AM, et.al.. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020 Sep 12;71(6):1367-1376. doi: 10.1093/cid/ciz1008.
• Meyer KC, Raghu G, Baughman RP, Brown KK, Costabel U, du Bois RM, Drent M, Haslam PL, Kim DS, Nagai S, Rottoli P, Saltini C, Selman M, Strange C, Wood B; American Thoracic Society Committee on BAL in Interstitial Lung Disease. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012 May 1;185(9):1004-14. doi: 10.1164/rccm.201202-0320ST.
• Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, Pastore D, Picardi M, Bonini A, Chierichini A, Fanci R, Caramatti C, Invernizzi R, Mattei D, Mitra ME, Melillo L, Aversa F, Van Lint MT, Falcucci P, Valentini CG, Girmenia C, Nosari A. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006 Aug;91(8):1068-75.
• Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis. 2005 Jun 15;40(12):1762-9. doi: 10.1086/429921.
• Heng SC, Chen SC, Morrissey CO, Thursky K, Manser RL, De Silva HD, Halliday CL, Seymour JF, Nation RL, Kong DC, Slavin MA. Clinical utility of Aspergillus galactomannan and PCR in bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in patients with haematological malignancies. Diagn Microbiol Infect Dis. 2014 Jul;79(3):322-7. doi: 10.1016/j.diagmicrobio.2014.03.020.
• Ozkalemkas F, Ozcelik T, Ozkocaman V. Treatment with piperacillin-tazobactam and Aspergillus galactomannan test results for patients with hematological malignancies. Eur J Intern Med. 2007 Jan;18(1):79. doi: 10.1016/j.ejim.2006.05.006.
• Heng SC, Morrissey O, Chen SC, Thursky K, Manser RL, Nation RL, Kong DC, Slavin M. Utility of bronchoalveolar lavage fluid galactomannan alone or in combination with PCR for the diagnosis of invasive aspergillosis in adult hematology patients: a systematic review and meta-analysis. Crit Rev Microbiol. 2015 Feb;41(1):124-34. doi: 10.3109/1040841X.2013.804033.
• Becker MJ, Lugtenburg EJ, Cornelissen JJ, Van Der Schee C, Hoogsteden HC, De Marie S. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol. 2003 May;121(3):448-57. doi: 10.1046/j.1365-2141.2003.04308.x.
• Racil Z, Kocmanova I, Toskova M, Buresova L, Weinbergerova B, Lengerova M, Rolencova M, Winterova J, Hrncirova K, Volfova P, Skrickova J, Mayer J. Galactomannan detection in bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in patients with hematological diseases-the role of factors affecting assay performance. Int J Infect Dis. 2011 Dec;15(12):e874-81. doi: 10.1016/j.ijid.2011.09.011.
• Nguyen MH, Leather H, Clancy CJ, Cline C, Jantz MA, Kulkarni V, Wheat LJ, Wingard JR. Galactomannan testing in bronchoalveolar lavage fluid facilitates the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies and stem cell transplant recipients. Biol Blood Marrow Transplant. 2011 Jul;17(7):1043-50. doi: 10.1016/j.bbmt.2010.11.013.
• Bergeron A, Belle A, Sulahian A, Lacroix C, Chevret S, Raffoux E, Arnulf B, Socié G, Ribaud P, Tazi A. Contribution of galactomannan antigen detection in BAL to the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. Chest. 2010 Feb;137(2):410-5. doi: 10.1378/chest.09-0701.
• Affolter K, Tamm M, Jahn K, Halter J, Passweg J, Hirsch HH, Stolz D. Galactomannan in bronchoalveolar lavage for diagnosing invasive fungal disease. Am J Respir Crit Care Med. 2014 Aug 1;190(3):309-17. doi: 10.1164/rccm.201403-0431OC.
• Özkocaman V, Özkalemkaş F, Seyhan S, Ener B, Ursavaş A, Ersal T, Kazak E, Demirdöğen E, Mıstık R, Akalın H. The Outcome of Antifungal Prophylaxis with Posaconazole in Patients with Acute Myeloid Leukemia: A Single-Center Study. Turk J Haematol. 2018 Nov 13;35(4):277-282. doi: 10.4274/tjh.2017.0430.